Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or T... ( ST. LOUIS March 3 /- Sigma-A...)

HOME >> BIOLOGY >> TECHNOLOGY

Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells

Date:3/3/2009

ST. LOUIS, March 3 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the global release of the MISSION(R) LentiPlex(TM) Pooled Human and Murine shRNA Libraries (http://www.sigma-aldrich.com/lentiplex). Using the shRNA collections of The RNAi Consortium (TRC), the MISSION LentiPlex Pooled shRNA Libraries enable rapid, genome-wide RNAi screening at the bench-top level in a convenient and powerful, pooled lentiviral format. As a member of both TRC-1 and TRC-2 collaborations, Sigma-Aldrich is the exclusive commercial source for access to TRC shRNA libraries in lentiviral format.

The MISSION LentiPlex Pooled shRNA Libraries were developed from the entire TRC-1 human and mouse collections of more than 158,000 shRNA constructs targeting approximately 16,000 human genes and approximately 16,000 mouse genes. Combining Sigma-Aldrich's high-throughput lentiviral production methodologies with the pooled library format enables researchers to perform genome-wide RNAi screens on various cell types, rapidly and efficiently discovering new targets without a large investment in infrastructure.

"Sigma-Aldrich is committed to providing customers powerful and unique screening formats that fully leverage the content of TRC," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich. "The pooled lentiviral format of this product is expected to make the discovery potential of the TRC collection accessible to any researcher with minimal reagent, time or capital equipment investment."

LentiPlex enables researchers to screen for novel phenotypes in relevant cell lines and study gene function and disease, both in standard cell lines and difficult cell types such as primary, non-dividing, growth-arrested or terminall
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute

Post Your Comments:

Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or T...( ST. LOUIS March 3 /- Sigma-A...)